Zacks Research Has Bullish Forecast for IRWD Q1 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities researchers at Zacks Research increased their Q1 2026 earnings per share estimates for Ironwood Pharmaceuticals in a research report issued on Tuesday, January 20th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings of $0.07 per share for the quarter, up from their prior estimate of $0.01. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at $0.40 EPS, FY2026 earnings at $0.98 EPS, Q2 2027 earnings at $0.02 EPS and Q4 2027 earnings at ($0.02) EPS.

Several other research firms also recently commented on IRWD. Craig Hallum raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Citigroup raised Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Weiss Ratings restated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Citizens Jmp upgraded Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 price target for the company in a report on Monday, January 5th. Finally, Wells Fargo & Company increased their price target on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the company an “equal weight” rating in a research report on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.74.

Ironwood Pharmaceuticals Trading Up 1.5%

Shares of IRWD stock opened at $5.39 on Thursday. The firm has a fifty day simple moving average of $3.73 and a two-hundred day simple moving average of $2.15. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $5.78. The firm has a market capitalization of $876.85 million, a PE ratio of 33.69 and a beta of 0.18.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. The company had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Range Financial Group LLC bought a new stake in Ironwood Pharmaceuticals in the fourth quarter worth about $1,436,000. Hennion & Walsh Asset Management Inc. grew its holdings in Ironwood Pharmaceuticals by 15.7% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 196,032 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 26,539 shares during the period. SG Americas Securities LLC increased its position in Ironwood Pharmaceuticals by 56.3% in the fourth quarter. SG Americas Securities LLC now owns 57,747 shares of the biotechnology company’s stock worth $195,000 after buying an additional 20,795 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in Ironwood Pharmaceuticals by 30.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,920,530 shares of the biotechnology company’s stock worth $2,516,000 after buying an additional 445,484 shares during the last quarter. Finally, Public Employees Retirement System of Ohio raised its stake in shares of Ironwood Pharmaceuticals by 351.2% in the third quarter. Public Employees Retirement System of Ohio now owns 60,768 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 47,299 shares during the period.

Ironwood Pharmaceuticals News Roundup

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Zacks sharply raised its FY2026 outlook — the firm boosted its full‑year 2026 EPS estimate from $0.39 to $0.98, and materially raised Q1, Q2 and Q3 2026 EPS forecasts (Q1 to $0.07, Q2 to $0.27, Q3 to $0.40). These upgrades imply stronger near‑term profitability expectations that can support multiple expansion and the stock’s move higher. MarketBeat IRWD
• Neutral Sentiment: Zacks maintained a “Strong‑Buy” rating on IRWD — the positive rating lends conviction to the estimate changes but is an analyst view rather than company guidance. Also, the consensus full‑year EPS shown in the report ($0.10) remains lower than Zacks’ internal FY2026 projection, indicating some divergence between Zacks and broader analyst consensus. MarketBeat IRWD
• Negative Sentiment: Zacks trimmed several 2027 quarter forecasts (e.g., Q3 2027 to ($0.01), Q4 2027 to ($0.02) and Q4 2027 earlier flagged as negative), signaling potential softening beyond 2026. Those cuts introduce risk to longer‑term growth assumptions and could pressure the stock if investors focus on sustainability of earnings. MarketBeat IRWD

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.